ArticleTranslational lung cancer research2025

Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.

Yusuke Kunimatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.